The purpose of this grant is to support the CALGB program in immunology and genetics through support of the Immunology and Genetics Committee Office at the University of Minnesota (UMN) and CALGB Central Reference Laboratories at the University of California at San Diego (UCSD), Dartmouth Medical School (DMS), University of North Carolina at Chapel Hill (UNC), Upstate Medical Center, syracuse (SYR), University of Chicago (UC), Columbia University (COL), Washington University (Wash U), and University of New Mexico (UNM). The major specific aims of current and proposed Immunology and Genetics studies are to define 1) the clinical significance of immunologic phenotyping with monoclonal antibodies in adult ALL (CALGB 8364), AML (8361) and CLL (8X6K), 2) the clinical significance of clonal excess in lymphoma (8363), 3) the clinical significance of chromosome analysis in adult leukemia (8461), CML (8583), and lymphoma (8X61), 4) the epidemiology of acute leukemia using cytogenetic classification (8661), 5) the seroepidemiology of HTLV-I in lymphoma, (8752), 6) the clinical significance of various gene rearrangements ((Ig and T-cell receptor (8X6E); bcr, abl (8X6A, 8X6C); bcl-2 (8X6I); bcl-1 (8X6K; N-ras, src, fgr, myc, myb, fos, mos, fms (8X6J)) in leukemia and lymphoma, and 7) the antitumor activity of interferon in hairy cell leukemia, lymphoma, Hodgkin's Disease, chronic myelogenous leukemia, and mulitple myeloma.
These specific aims will be accomplished through 12 ongoing and 2 closed group-wide CALGB studies and 6 protocols that are in the process of activation. The Immunology and Genetics Committee is chaired by Clara D. Bloomfield, M.D. (UMN). The Vice-Chairs are for Immunology Ivor Royston, M.D. (UCSD), for Cytogenetics Doris Wurster-Hill, Ph.D. (DMS), and for Molecular Genetics Stanely Korseyer, M.D. (Wash U). The program is developed, coordinated and administered (fiscally and otherwise) through the Immunology and Genetics Committee Office at the University of Minnesota. This office also collects, reviews, computerizes, and analyzes all of the cytogenetic data (including karyotypes). This office distributes monies to the various Central Reference Laboratories through subcontracts. Each Central Reference Laboratory is responsible for collecting and analyzing data for specific studies as follows: UCSD, 8364, 8X6K; DMS, 8361, 8X6J; UNC, 8363; UC, 8X6C; COL, 8X6A; Wash U, 8X61; SYR, 8752; UNM, 8X6J. The proposed research should increase our understanding of the biology of the hematologic malignancies as well as result in improved ability to diagnose (and classify) and treat adults with leukemia and lyphoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA037027-05
Application #
3557942
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1984-04-01
Project End
1993-03-31
Budget Start
1988-04-01
Budget End
1989-03-31
Support Year
5
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
Schools of Medicine
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Douer, Dan; Zickl, Lynette N; Schiffer, Charles A et al. (2013) All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129. Leuk Res 37:795-801
Tallman, Martin S; Andersen, Janet W; Schiffer, Charles A et al. (2002) All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100:4298-302
O'Dwyer, P J; Manola, J; Valone, F H et al. (2001) Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cance J Clin Oncol 19:2413-21
Larson, R A (2000) Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am 14:1367-79, x
Heinonen, K; Mrozek, K; Lawrence, D et al. (1998) Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study. Br J Haematol 101:513-20
Baer, M R; Stewart, C C; Lawrence, D et al. (1998) Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia 12:317-25
Caligiuri, M A; Strout, M P; Lawrence, D et al. (1998) Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 58:55-9
Larson, R A; Dodge, R K; Linker, C A et al. (1998) A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 92:1556-64
Baer, M R; Stewart, C C; Lawrence, D et al. (1997) Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 90:1643-8
Mrozek, K; Heinonen, K; Lawrence, D et al. (1997) Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood 90:4532-8

Showing the most recent 10 out of 45 publications